N/A N=214 Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
Antibiotics Associated Colitis · Pulmonary Infection
Primary: Presence of AAD — 12 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=98 Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis
Appendicitis · Appendicitis; Perforation
Primary: Length of Hospital Stay — 121.55; 131.69 hours
Phase 4 N=14 Effects of Gastric Acid on Colonic Microbiome
Clostridium Difficile
Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71
Early Phase 1 N=66 Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
Antibiotic-associated Diarrhea
Primary: Level of Fecal Short-chain Fatty Acid (SCFA) Acetate — 53.1; 45.2; 42.3; 38.1 micromolar (μM)
Early Phase 1 N=118 Mechanisms of Probiotics and Antibiotic-Associated Diarrhea
Antibiotic-associated Diarrhea
Primary: Change From Baseline Levels of Fecal Short-chain Fatty Acid (With a Particular Focus on Acetate) — 23.55; -13.9; -19.5; 7.25 micromolar
Phase 4 N=33 Impact of Oral Antibiotic Treatment on C. Difficile
C. Difficile · Diarrhea · Enterocolitis
Primary: Change in Total Median Total Colony Forming Units (CFU) of C. Difficile Identified in the Hospital Room Environment for Each Antibiotic Treatment Group. — 56; 33; 149; 7…
Phase 3 N=437 Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
Diarrhea · Clostridium Infections
Primary: The Incidence of Antibiotic-associated Diarrhea. — 216; 221 participants
Phase 4 N=51 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
Clostridium Difficile Infection · Prophylaxis · Vancomycin
Primary: Clostridium Difficile Infection Occurrence — 2; 0 Participants
Phase 3 N=259 Antibiotic Safety (SCAMP)
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
Phase 4 N=10 Effect of Antibiotics on Enteric Neurons and Glia
Antibiotic Enterocolitis
Primary: Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment — 0 neuronal cells/mm^2
Phase 3 N=255 Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection
Antibiotic-Associated Diarrhea · Clostridium Difficile-Associated Diarrhea
Primary: To Assess if Probiotic Prophylaxis (BIO-K+CL1285®) is Effective for the Prevention of AAD in Hospitalized Patients. — 84; 85; 86 participants — p==0.02
N/A N=53 Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota
Healthy Volunteers
Primary: Gastrointestinal Symptom Rating Scale — 18.7; 18.7; 17.3 units on a scale
N/A N=32 Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota
Human Gut Microbiota
Primary: Bacteria Prevalence in Stool — 22.3; 20.9; 18.0; 25.5 percentage of bacterial genera in stool — p=<0.05
Phase 4 N=8 Effects of Intravenous (IV) Omadacycline on Gut Microbiome
Microbial Colonization
Primary: Phylum Level Mean Proportional Relative Abundance — 0.167; 0.0271; 0.686; 0.0391 % gram positive (+) for phylum
Phase 4 N=144 A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
Clostridium Difficile Infection (CDI)
Primary: Clinical Cure: Resolution of Diarrhea — 54; 44 Participants — p=0.195
Phase 2 N=98 Antibiotic "Dysbiosis" in Preterm Infants
Enterocolitis, Necrotizing · Bacteremia · Bronchopulmonary Dysplasia
Primary: Number of Events of Composite Morbidities and Mortality, Including Necrotizing Enterocolitis (NEC), Late Onset Sepsis (LOS), Bronchopulmonary Dysplasia (BPD) and Death…
Phase 3 N=606 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT) — 79.0; 83.6 Percentage of participants
Phase 4 N=9 C. Difficile and Ursodiol
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants
Phase 3 N=69 Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Rectal Cancer
Primary: Number of Participants Who Completed MSKCC Bowel Function Instrument (BFI Score) in Patients Following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for…
Phase 2 N=90 Continuous Antibiotic Prophylaxis in Colorectal Surgery
Surgical Site Infection
Primary: Number of Patients With a Surgical Site Infection — 10; 13 Participants
Phase 4 N=15 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
N/A N=92 Dietary Supplement With and Without a Probiotic and/or Antibiotic
Healthy Adults
Primary: Evaluation of the Changes in Microbiome Species Abundance and Diversity From Baseline Until End of Study (Day 35) — 27.00; 31.25; 27.00; 27.00 copies/ng DNA — p=<0.0001
Phase 2 N=33 Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease
Crohn's Disease
Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events
Phase 2 N=255 Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics
Antibiotic-associated Diarrhea
Primary: Number of Participants Experiencing Diarrhea — 3; 2; 122; 128 Participants
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
Phase 2 N=10 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
Phase 4 N=510 Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Infection
Primary: Number of Participants With Post-biopsy Infection. — 6; 3 participants — p=<0.05
Phase 2 N=34 Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
Recurrent Clostridium Difficile Infection
Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days
Phase 3 N=92 Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
Recurrent Clostridium Difficile Infection · Primary Clostridium Difficile Infection
Primary: Global Absence of Diarrhea Due to Clostridiodes Difficile 8 Weeks After the Start of the Treatment — 4; 9 Participants — p=0.228
Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events